drugset / Trial / NCT04144517
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
Timeline
- Start
- 2020-02-05
- Primary completion
- 2021-10-08
- Completion
- 2022-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemvaleukin Alfa | Protein / enzyme biologic | 3 ug/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |